The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis

Matthew A. Rank; Derek K. Chu; Antonio Bognanni; Paul Oykhman; Jonathan A. Bernstein; Anne K. Ellis; David B.K. Golden; Matthew Greenhawt; Caroline C. Horner; Dennis K. Ledford; Jay Lieberman; Amber U. Luong; Richard R. Orlandi; Shefali A. Samant; Marcus S. Shaker; Zachary M. Soler; Whitney W. Stevens; David R. Stukus; Julie Wang; Anju T. Peters

doi:10.1016/j.jaci.2022.10.026

The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis

Matthew A. Rank, Derek K. Chu, Antonio Bognanni, Paul Oykhman, Jonathan A. Bernstein, Anne K. Ellis, David B.K. Golden^*, Matthew Greenhawt, Caroline C. Horner, Dennis K. Ledford, Jay Lieberman, Amber U. Luong, Richard R. Orlandi, Shefali A. Samant, Marcus S. Shaker, Zachary M. Soler, Whitney W. Stevens, David R. Stukus, Julie Wang, Anju T. Peters

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). It is important to note that the current evidence on surgery for CRSwNP was not assessed for this guideline nor were management options other than INCS, biologics, and ATAD. The Allergy-Immunology Joint Task Force on Practice Parameters formed a multidisciplinary guideline panel balanced to include the views of multiple stakeholders and to minimize potential biases. Systematic reviews for each management option informed the guideline. The guideline panel used the Grading of Recommendations Assessment, Development and Evaluation approach to inform and develop recommendations. The guideline panel reached consensus on the following statements: (1) In people with CRSwNP, the guideline panel suggests INCS rather than no INCS (conditional recommendation, low certainty of evidence). (2) In people with CRSwNP, the guideline panel suggests biologics rather than no biologics (conditional recommendation, moderate certainty of evidence). (3) In people with aspirin (nonsteroidal anti-inflammatory drug)-exacerbated respiratory disease, the guideline panel suggests ATAD rather than no ATAD (conditional recommendation, moderate certainty of evidence). The conditions for each recommendation are discussed in the guideline.

Original language	English (US)
Pages (from-to)	386-398
Number of pages	13
Journal	Journal of Allergy and Clinical Immunology
Volume	151
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2022.10.026
State	Published - Feb 2023

Funding

Disclosure of potential conflict of interest: J.A. Bernstein reports consulting and/or speaking for Mylan, ALK-Abelló, Pharvaris, Celldex Therapeutics, Ionis, Amgen, Blueprint Medicine, BioMarin Pharmaceutical, GSK, OptiNose, CSL Behring, KalVista Pharmaceuticals, Merck, GI, Allakos, Teva Pharmaceuticals, Akarin, Sanofi Regeneron, AstraZeneca, Novartis, Genentech, Pharming, BioCryst Pharmaceuticals, and Shire/Takeda. A.K. Ellis reports consulting for GSK; speaking for Bausch Health, ALK-Abelló, AstraZeneca, GSK, Pfizer, Medexus Pharmaceuticals, and CSL Behring; and serving on advisory board for AbbVie, ALK-Abelló, and Novartis. D.B.K. Golden reports consulting with ALK-Abelló, Thermo Fisher Scientific , LabCorp, Allergy Therapeutics, and Novartis; speaking for Genentech; serving on an advisory board for Aquestive Therapeutics; and clinical trials support from Regeneron , Pfizer , Merch, Roche , GSK, and Aimmune Therapeutics . M. Greenhawt reports serving on an advisory board for Allergy Therapeutics, Allergenis, Sanofi Regeneron, Pfizer, US World Meds, Prota Therapeutics, Aquestive, Novartis, Intrommune Therapeutics, and DBV Technologies. D.K. Ledford reports consulting with AstraZeneca/Amgen, GSK, and BioCryst; speaking for Sanofi Regeneron, Genentech, Abbot, AstraZeneca/Amgen, and GSK; and serving on an advisory board for AstraZeneca/Amgen. J. Lieberman reports speaking for Genentech and serving on advisory boards for ALK-Abelló, DBV, and Novartis. M. Shaker participated in research funded by DBV. W.W. Stevens reports serving on an advisory board for GSK. D.R. Stukus reports consulting with Before Brands, Integrity CE, Kaléo, and Novartis. A.U. Luong reports consulting with Stryker, Medtronic, Sanofi, and Lyra Therapeutics, and serving on advisory boards for AstraZeneca, ENTvantage Diagnostics, and GSK. Z.M. Soler reports on consulting for OptiNose, Lyra, and GSK. J. Wang reports consulting for ALK-Abelló, Jubilant HollisterStier, Food Allergy Research and Education, and Genentech. A.T. Peters reports consulting with OptiNose and Sanofi Regeneron, and serving on advisory boards for GSK and AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest.

Keywords

Chronic rhinosinusitis
aspirin
biologics
clinical guideline
corticosteroids
nasal polyposis

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2022.10.026

Cite this

Rank, M. A., Chu, D. K., Bognanni, A., Oykhman, P., Bernstein, J. A., Ellis, A. K., Golden, D. B. K., Greenhawt, M., Horner, C. C., Ledford, D. K., Lieberman, J., Luong, A. U., Orlandi, R. R., Samant, S. A., Shaker, M. S., Soler, Z. M., Stevens, W. W., Stukus, D. R., Wang, J., & Peters, A. T. (2023). The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. Journal of Allergy and Clinical Immunology, 151(2), 386-398. https://doi.org/10.1016/j.jaci.2022.10.026

@article{2a5917c59d524710bb9399ab36129cb5,

title = "The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis",

abstract = "These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). It is important to note that the current evidence on surgery for CRSwNP was not assessed for this guideline nor were management options other than INCS, biologics, and ATAD. The Allergy-Immunology Joint Task Force on Practice Parameters formed a multidisciplinary guideline panel balanced to include the views of multiple stakeholders and to minimize potential biases. Systematic reviews for each management option informed the guideline. The guideline panel used the Grading of Recommendations Assessment, Development and Evaluation approach to inform and develop recommendations. The guideline panel reached consensus on the following statements: (1) In people with CRSwNP, the guideline panel suggests INCS rather than no INCS (conditional recommendation, low certainty of evidence). (2) In people with CRSwNP, the guideline panel suggests biologics rather than no biologics (conditional recommendation, moderate certainty of evidence). (3) In people with aspirin (nonsteroidal anti-inflammatory drug)-exacerbated respiratory disease, the guideline panel suggests ATAD rather than no ATAD (conditional recommendation, moderate certainty of evidence). The conditions for each recommendation are discussed in the guideline.",

keywords = "Chronic rhinosinusitis, aspirin, biologics, clinical guideline, corticosteroids, nasal polyposis",

author = "Rank, {Matthew A.} and Chu, {Derek K.} and Antonio Bognanni and Paul Oykhman and Bernstein, {Jonathan A.} and Ellis, {Anne K.} and Golden, {David B.K.} and Matthew Greenhawt and Horner, {Caroline C.} and Ledford, {Dennis K.} and Jay Lieberman and Luong, {Amber U.} and Orlandi, {Richard R.} and Samant, {Shefali A.} and Shaker, {Marcus S.} and Soler, {Zachary M.} and Stevens, {Whitney W.} and Stukus, {David R.} and Julie Wang and Peters, {Anju T.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Academy of Allergy, Asthma & Immunology",

year = "2023",

month = feb,

doi = "10.1016/j.jaci.2022.10.026",

language = "English (US)",

volume = "151",

pages = "386--398",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "2",

}

Rank, MA, Chu, DK, Bognanni, A, Oykhman, P, Bernstein, JA, Ellis, AK, Golden, DBK, Greenhawt, M, Horner, CC, Ledford, DK, Lieberman, J, Luong, AU, Orlandi, RR, Samant, SA, Shaker, MS, Soler, ZM, Stevens, WW, Stukus, DR, Wang, J & Peters, AT 2023, 'The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis', Journal of Allergy and Clinical Immunology, vol. 151, no. 2, pp. 386-398. https://doi.org/10.1016/j.jaci.2022.10.026

TY - JOUR

T1 - The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis

AU - Rank, Matthew A.

AU - Chu, Derek K.

AU - Bognanni, Antonio

AU - Oykhman, Paul

AU - Bernstein, Jonathan A.

AU - Ellis, Anne K.

AU - Golden, David B.K.

AU - Greenhawt, Matthew

AU - Horner, Caroline C.

AU - Ledford, Dennis K.

AU - Lieberman, Jay

AU - Luong, Amber U.

AU - Orlandi, Richard R.

AU - Samant, Shefali A.

AU - Shaker, Marcus S.

AU - Soler, Zachary M.

AU - Stevens, Whitney W.

AU - Stukus, David R.

AU - Wang, Julie

AU - Peters, Anju T.

PY - 2023/2

Y1 - 2023/2

N2 - These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). It is important to note that the current evidence on surgery for CRSwNP was not assessed for this guideline nor were management options other than INCS, biologics, and ATAD. The Allergy-Immunology Joint Task Force on Practice Parameters formed a multidisciplinary guideline panel balanced to include the views of multiple stakeholders and to minimize potential biases. Systematic reviews for each management option informed the guideline. The guideline panel used the Grading of Recommendations Assessment, Development and Evaluation approach to inform and develop recommendations. The guideline panel reached consensus on the following statements: (1) In people with CRSwNP, the guideline panel suggests INCS rather than no INCS (conditional recommendation, low certainty of evidence). (2) In people with CRSwNP, the guideline panel suggests biologics rather than no biologics (conditional recommendation, moderate certainty of evidence). (3) In people with aspirin (nonsteroidal anti-inflammatory drug)-exacerbated respiratory disease, the guideline panel suggests ATAD rather than no ATAD (conditional recommendation, moderate certainty of evidence). The conditions for each recommendation are discussed in the guideline.

AB - These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). It is important to note that the current evidence on surgery for CRSwNP was not assessed for this guideline nor were management options other than INCS, biologics, and ATAD. The Allergy-Immunology Joint Task Force on Practice Parameters formed a multidisciplinary guideline panel balanced to include the views of multiple stakeholders and to minimize potential biases. Systematic reviews for each management option informed the guideline. The guideline panel used the Grading of Recommendations Assessment, Development and Evaluation approach to inform and develop recommendations. The guideline panel reached consensus on the following statements: (1) In people with CRSwNP, the guideline panel suggests INCS rather than no INCS (conditional recommendation, low certainty of evidence). (2) In people with CRSwNP, the guideline panel suggests biologics rather than no biologics (conditional recommendation, moderate certainty of evidence). (3) In people with aspirin (nonsteroidal anti-inflammatory drug)-exacerbated respiratory disease, the guideline panel suggests ATAD rather than no ATAD (conditional recommendation, moderate certainty of evidence). The conditions for each recommendation are discussed in the guideline.

KW - Chronic rhinosinusitis

KW - aspirin

KW - biologics

KW - clinical guideline

KW - corticosteroids

KW - nasal polyposis

UR - http://www.scopus.com/inward/record.url?scp=85143870176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85143870176&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2022.10.026

DO - 10.1016/j.jaci.2022.10.026

M3 - Article

C2 - 36370881

AN - SCOPUS:85143870176

SN - 0091-6749

VL - 151

SP - 386

EP - 398

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 2

ER -

The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this